BP-1.3656B is under clinical development by Bioprojet SCR and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect BP-1.3656B’s likelihood of approval (LoA) and phase transition for Alcohol Addiction took place on 25 Jan 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their BP-1.3656B Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
BP-1.3656B is under development for the treatment of central nervous system disorders including alcohol use disorder, fatigue following ischemic stroke. It is administered through the oral route. It acts as a histamine receptor 3 (HT3) antagonist. It was also under development for other central nervous system disorders.
Bioprojet SCR overview
Bioprojet SCR (Bioprojet) operates as a drug development company. The company offers anapen, an auto-injector pen for the immediate treatment of anaphylactic shock; tiorfan, an intestinal anti-secretory drug for the treatment of acute diarrhoea; and wakix, a histamine H3 receptor antagonist and agonist inverse for the treatment of drowsiness with or without cataplexy. It develops drugs in the therapeutic areas of gastro enterology, cardiovascular, central nervous system, and other compounds in preclinical development. The company distributes its products to 70 countries in Europe, Africa, Asia and Latin America. Bioprojet is headquartered in Paris, France.
Quick View BP-1.3656B LOA Data
|Highest Development Stage|